NASDAQ:IG

Principal Investment Grade Corporate Active Etf Principal Investment Grade Corporate Active Etf ETF News

Financial Services > Asset Management

Buy IG

*Your capital is at risk

$20.59

-0.0600 (-0.291%)

At Close: Jun 22, 2026

IGI Laboratories, Inc. Reports Q2 EPS of $(0.01) vs $0.00 Est; Revenue of $3.82M vs $3.61M Est

12:00am, Thursday, 25'th Jul 2013

IGI Laboratories, Inc. Announces Eleventh Abbreviated New Drug Application Submission

12:00am, Wednesday, 24'th Jul 2013

IGI Laboratories, Inc. Reports Q1 EPS of $(0.01) vs $0.00 Est; Revenue of $3.68M vs $2.40M Est

12:00am, Friday, 26'th Apr 2013

IGI Laboratories, Inc. Reports Q1 EPS of $0.01 vs $0.00 Est; Revenue of $3.68M vs $2.40M Est

12:00am, Thursday, 25'th Apr 2013

IGI Inc Reports Operating Results (10-Q)

12:00am, Wednesday, 14'th Nov 2012

IGI Laboratories Reports Q3 EPS $-0.04 vs $0.00 Est; Revenues $2.0M vs $3.18M Est

12:00am, Tuesday, 13'th Nov 2012

Benzinga's Microcap Movers for Friday September 7, 2012

12:00am, Saturday, 08'th Sep 2012

IGI Inc (IG) CEO Jason Grenfell-gardner buys 10,000 Shares

12:00am, Thursday, 16'th Aug 2012

IGI Labs Reports Q2 EPS $-0.01; Revenues $2.44M

12:00am, Monday, 13'th Aug 2012

IGI Laboratories Announces the Submission of Two More ANDAs

12:00am, Friday, 29'th Jun 2012

IGI Laboratories Announces the Submission of Sixth ANDA

12:00am, Tuesday, 05'th Jun 2012

IGI Inc Reports Operating Results (10-K)

12:00am, Thursday, 29'th Mar 2012

IGI Laboratories Announces the Submission of Fifth ANDA

12:00am, Thursday, 29'th Dec 2011

Principal Investment Grade Corporate Active Etf Principal Investment Grade Corporate Active Etf ETF News

IGI Laboratories, Inc. Reports Q2 EPS of $(0.01) vs $0.00 Est; Revenue of $3.82M vs $3.61M Est

IGI Laboratories, Inc. Announces Eleventh Abbreviated New Drug Application Submission

IGI Laboratories, Inc. Reports Q1 EPS of $(0.01) vs $0.00 Est; Revenue of $3.68M vs $2.40M Est

IGI Laboratories, Inc. Reports Q1 EPS of $0.01 vs $0.00 Est; Revenue of $3.68M vs $2.40M Est

IGI Inc Reports Operating Results (10-Q)

IGI Laboratories Reports Q3 EPS $-0.04 vs $0.00 Est; Revenues $2.0M vs $3.18M Est

Benzinga's Microcap Movers for Friday September 7, 2012

IGI Inc (IG) CEO Jason Grenfell-gardner buys 10,000 Shares

IGI Labs Reports Q2 EPS $-0.01; Revenues $2.44M

IGI Laboratories Announces the Submission of Two More ANDAs

IGI Laboratories Announces the Submission of Sixth ANDA

IGI Inc Reports Operating Results (10-K)

IGI Laboratories Announces the Submission of Fifth ANDA

IGI Laboratories, Inc. and Medimetriks Pharmaceuticals, Inc. Enter Long Term Strategic Partnership

IGI Laboratories Announces the Submission of Two More ANDAs

Top Fintech Company